Skip to main content
Article thumbnail
Location of Repository

Life or cell death: identifying c-Myc regulated genes in two distinct tissues

By Samuel Charles Robson

Abstract

The c-myc oncogene is over-expressed or deregulated in many human cancers. c-myc encodes a transcription factor, the oncoprotein c-Myc (Myc), which acts as a master regulator of genes involved in such diverse cellular processes as replication and growth, loss of differentiation, invasion, and angiogenesis. Myc can also act as its own tumour suppressor by promoting cell death in the form of apoptosis. Thus, for putative cancer cells to arise, apoptosis must be blocked. Conditional MycERTAM transgenic mice allow regulated activation of Myc in distinct cell populations (skin suprabasal keratinocytes and pancreatic islet β-cells) and have highlighted contrasting behaviour between these two adult tissues in vivo: proliferation in the skin, and apoptosis in the pancreas. Given the crucial dependence on tissue location in vivo, we still do not know enough about the key divergence in Myc-regulated genes and proteins under conditions favouring opposing outcomes. To address this, we performed high-throughput transcriptome analysis using oligonucleotide microarrays. The in vivo transcriptional response to deregulated Myc was analysed for skin keratinocytes and laser-captured pancreatic islets following a time-course of MycERTAM activation. Due to the multi-factorial nature of the experimental design, novel statistical tools were developed allowing the use of linear models for inference of changes in gene-expression based on multiple experimental variables. Comparison of the transcriptional response between the two tissues identified potential signalling pathways which may promote apoptosis of β-cells or survival of skin keratinocytes: the DNA damage response pathway, and the Insulin-like growth factor 1 (Igf1) signalling pathway respectively. In addition, a marked change in expression was detected in members of the steroid hormone-regulated Kallikrein serine protease family in suprabasal keratinocytes but not for β-cells. These have been found to play an important role in regulating Igf1/Igf1-receptor ligation through proteolysis of the Igf1 binding proteins, are previously categorised markers for several human cancers, and may indicate a tissue-specific regulatory mechanism for determining ultimate Myc function in vivo

Topics: QH426
OAI identifier: oai:wrap.warwick.ac.uk:1064

Suggested articles

Citations

  1. (1999). [Genetic transcription in eukaryotes: from transcriptional factors to disease].
  2. (1951). [The insular alpha and beta cells as the source of the antagonistic principles glucagon and insulin.].
  3. (2005). 385 Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays.
  4. (2001). A Bayesian framework for the analysis of microarray expression data: regularized t -test and statistical inferences of gene changes.
  5. (1998). A cellular repressor of E1A-stimulated genes that inhibits activation by E2F.
  6. (2003). A comparison of normalization methods for high density oligonucleotide array data based on variance and bias.
  7. (1995). A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein binding functions.
  8. (2005). A conserved element in Myc that negatively regulates its proapoptotic activity.
  9. (2006). A conserved Myc protein domain, MBIV, regulates DNA binding, apoptosis, transformation, and G2 arrest.
  10. (2002). A direct approach to false discovery rates.
  11. (1997). A DNA helicase activity is associated with an MCM4, -6, and -7 protein complex.
  12. (1996). A DNA microarray system for analyzing complex DNA samples using two-color fluorescent probe hybridization.
  13. (2007). A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer.
  14. (2003). A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells.
  15. (2005). A haplotype map of the human genome.
  16. (1979). A k-means clustering algorithm.
  17. (2003). A large scale genetic analysis of c-Myc-regulated gene expression patterns.
  18. (2004). A Model Based Background Adjustment for Oligonucleotide Expression Arrays.
  19. (1995). A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins.
  20. (2000). A mutation in the c-myc-IRES leads to enhanced internal ribosome entry in multiple myeloma: a novel mechanism of oncogene de-regulation. Oncogene,
  21. (1974). A new look at the statistical model identification.
  22. (1997). A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma.
  23. (2003). A novel technique for the examination of skin biopsies by laser capture microdissection.
  24. (2001). A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis.
  25. (2001). A novel, high conductance channel of mitochondria linked to apoptosis in mammalian cells and Bax expression in yeast.
  26. (1993). A null c-myc mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice.
  27. (2006). A reanalysis of a published Affymetrix GeneChip control dataset.
  28. (1999). A role for ATR in the DNA damage-induced phosphorylation of p53.
  29. (2003). A role for c-Myc in the regulation of ribosomal RNA processing.
  30. (2007). A second generation human haplotype map of over 3.1 million SNPs.
  31. (2006). A simple spreadsheet-based, MIAME-supportive format for microarray data:
  32. (2007). A single type of progenitor cell maintains normal epidermis.
  33. (2002). A statistical framework for expression-based molecular classification in cancer.
  34. (2002). A systematic statistical linear modeling approach to oligonucleotide array experiments.
  35. (2002). A variance-stabilizing transformation for gene-expression microarray data.
  36. (2006). Ablation of PDK1 in pancreatic beta cells induces diabetes as a result of loss of beta cell mass.
  37. (2003). Accurate and reproducible gene expression profiles from laser capture microdissection, transcript amplification, and high density oligonucleotide microarray analysis.
  38. (1998). Activation of the ATM kinase by ionizing radiation and phosphorylation of p53.
  39. (2005). Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions.
  40. (2000). Activation of the human estrogen receptor by the antiestrogens ICI 182,780 and tamoxifen in yeast genetic systems: implications for their mechanism of action.
  41. (1997). Adding semantics to genome databases: towards an ontology for molecular biology.
  42. (1993). Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at nearphysiological insulinotropic hormone and glucose concentrations.
  43. (1995). Aging skin.
  44. (1983). Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour.
  45. (1990). Amplified RNA synthesized from limited quantities of heterogeneous cDNA.
  46. (1997). An alternative pathway for gene regulation by Myc.
  47. (2005). An array of problems.
  48. (1975). An endotoxin-induced serum factor that causes necrosis of tumors.
  49. (1996). An essential E box in the promoter of the gene encoding the mRNA cap-binding protein (eukaryotic initiation factor 4E) is a target for activation by c-myc.
  50. (1995). An immunocytochemical and morphometric study of the rat pancreatic islets.
  51. (2003). An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets.
  52. (2002). An R and S-PLUS Companion to Applied Regression.
  53. (1982). Analysis of a simple self-organising process.
  54. (2006). Analysis of Affymetrix GeneChip data using amplified RNA.
  55. (2001). Analysis of C-MYC function in normal cells via conditional gene-targeted mutation.
  56. (2004). Analysis of genomic targets reveals complex functions of MYC.
  57. (2000). Analysis of p53-regulated gene expression patterns using oligonucleotide arrays.
  58. (2000). Analysis of variance for gene expression microarray data.
  59. (2000). Analyzing high-density oligonucleotide gene expression array data.
  60. (1972). Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics.
  61. (1992). Apoptotic cell death induced by c-myc is inhibited by bcl-2.
  62. (2006). Application of in situ ductal perfusion to facilitate isolation of high-quality RNA from mouse pancreas.
  63. (2004). Are data from different gene expression microarray platforms comparable?
  64. (2005). ARF and ATM/ATR cooperate in p53-mediated apoptosis upon oncogenic stress.
  65. (1998). ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways.
  66. (2006). Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse.
  67. (2003). ArrayExpress--a public repository for microarray gene expression data at the EBI.
  68. (2001). Assessing gene significance from cDNA microarray expression data via mixed models.
  69. (2006). Assessment of the 396 relationship between pre-chip and post-chip quality measures for Affymetrix GeneChip expression data.
  70. (2003). Ataxiatelangiectasia-mutated (ATM) and NBS1-dependent phosphorylation of Chk1 on Ser-317 in response to ionizing radiation.
  71. (2001). ATM and ATR: networking cellular responses to DNA damage.
  72. (2007). Atm deficiency affects both apoptosis and proliferation to augment Myc-induced lymphomagenesis.
  73. (2006). ATM promotes 409 apoptosis and suppresses tumorigenesis in response to Myc.
  74. (2001). ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1.
  75. (1998). Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization.
  76. (1979). Avian acute leukemia viruses MC29 and MH2 share specific RNA sequences: evidence for a second class of transforming genes.
  77. (1990). Basic local alignment search tool.
  78. (2000). Bax is a transcriptional target and mediator of c-mycinduced apoptosis.
  79. (1996). Bcl-2 inhibits the mitochondrial release of an apoptogenic protease.
  80. (2007). Bcl-2-regulated apoptosis: mechanism and therapeutic potential.
  81. (1996). bcl-w, a novel member of the bcl-2 family, promotes cell survival.
  82. (2006). Bcl-xL gain of function and p19 ARF loss of function cooperate oncogenically with Myc in vivo by distinct mechanisms.
  83. (1990). BCL2-mediated tumorigenicity of a human T-lymphoid cell 410 line: synergy with MYC and inhibition by BCL2 antisense.
  84. (1986). Behavior of myc and ras oncogenes in transformation of rat embryo fibroblasts.
  85. (1869). Beitrag zur mikroskopischen: Anatomie der Bauchspeicheldrüse. Inaugural
  86. (1994). BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax.
  87. (2000). Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane.
  88. (1998). Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors.
  89. BID: a novel BH3 domain-only death agonist.
  90. (1998). Bim: a novel member of the Bcl-2 family that promotes apoptosis.
  91. (1993). Binding of myc proteins to canonical and noncanonical DNA sequences.
  92. (2005). BiNGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks.
  93. (2004). Bioconductor: open software development for computational biology and bioinformatics.
  94. (1984). Biological activities of v-myc and rearranged c-myc oncogenes in rat fibroblast cells in culture.
  95. (1999). Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev,
  96. (2001). Breaking the mitochondrial barrier.
  97. (2004). Brief inactivation of c-Myc is not sufficient for sustained regression of cMyc-induced tumours of pancreatic islets and skin epidermis.
  98. (1999). Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays.
  99. (2006). c-Myc and downstream targets in the pathogenesis and treatment of cancer. Recent Patents Anticancer Drug Discov,
  100. (2003). c-MYC apoptotic function is mediated by NRF-1 target genes.
  101. (2002). c-Myc can induce DNA damage, increase reactive oxygen 418 species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability.
  102. (1999). c-Myc enhances protein synthesis and cell size during B lymphocyte development.
  103. (2002). c-Myc functionally cooperates with Bax to induce apoptosis.
  104. (1994). c-Myc induces cellular susceptibility to the cytotoxic action of TNF-alpha.
  105. (2004). c-Myc interacts with hypoxia to induce angiogenesis in vivo by a vascular endothelial growth factor-dependent mechanism.
  106. (1997). c-Myc promotes differentiation of human epidermal stem cells.
  107. (2000). c-Myc proteolysis by the ubiquitinproteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells.
  108. (2001). c-Myc regulates mammalian body size by controlling cell number but not cell size.
  109. (1999). c-Myc target genes involved in cell growth, apoptosis, and metabolism.
  110. (2003). c-Myc-induced genomic instability.
  111. (1999). c-Myc-induced sensitization to apoptosis is mediated through cytochrome c release.
  112. (2002). c-MYC: more than just a matter of life and death.
  113. (1994). c-Mycinduced apoptosis in fibroblasts is inhibited by specific cytokines.
  114. (2003). Cancer revoked: oncogenes as therapeutic targets.
  115. (1974). Candidate hormones of the gut. VI. Bovine pancreatic polypeptide (BPP) and avian pancreatic polypeptide (APP).
  116. (2007). Cdk1 is sufficient to drive the mammalian cell cycle.
  117. (2005). Cell cycle sibling rivalry:
  118. (1980). Cell death: the significance of apoptosis.
  119. (2004). Cell division and cell survival in the absence of survivin.
  120. (1997). Cell growth inhibition by the Mad/Max complex through recruitment of histone deacetylase activity.
  121. (2002). Characterization of the c-MYC-regulated transcriptome by SAGE: identification and analysis of c-MYC target genes.
  122. (2007). Characterization of the effect of sample quality on high density oligonucleotide microarray data using progressively degraded rat liver RNA.
  123. (2006). ChIP-on-chip protocol for genome-wide analysis of transcription factor binding in Drosophila melanogaster embryos.
  124. (2000). Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint.
  125. (2000). Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53.
  126. (2001). Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses.
  127. (1998). Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis.
  128. (2000). Cloning and characterization of mouse klk27, a novel tissue kallikrein expressed in testicular Leydig cells and exhibiting chymotrypsin-like specificity.
  129. (1998). Cluster analysis and display of genome-wide expression patterns.
  130. (1997). Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen.
  131. (2007). Comparative analysis of microarray normalization procedures: effects on reverse engineering gene networks.
  132. (2000). Comparative microarray analysis of gene expression during apoptosis-induction by growth factor deprivation or protein kinase C inhibition. Oncogene,
  133. (1997). Comparative sequence analysis of ribonucleases HII, III,
  134. (2003). Comparing the use of Affymetrix to spotted oligonucleotide microarrays using two retinal pigment epithelium cell lines.
  135. (2003). Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC-3 subcutaneous xenografts.
  136. (2002). Comprehensive comparison of six microarray technologies.
  137. (1998). Comprehensive identification of cell cycle-regulated genes of the yeast Saccharomyces cerevisiae by microarray hybridization.
  138. (1969). Concerning Least Squares Analysis of Experimental Data.
  139. (2002). Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis.
  140. (2004). Conditional animal models: a strategy to define when oncogenes will be effective targets to treat cancer.
  141. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis.
  142. (1986). Constitutive c-myc oncogene expression blocks mouse erythroleukaemia cell differentiation but not commitment.
  143. (1999). Control of cell growth by c-Myc in the absence of cell division.
  144. (1999). Control of cell proliferation by Myc family genes.
  145. (2007). Control of the mean number of false discoveries, bonferroni and stability of multiple testing.
  146. (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing.
  147. (1992). Cooperative interaction between c-myc and bcl-2 proto-oncogenes.
  148. (1986). CpG-rich islands and the function of DNA methylation.
  149. (2005). Cross-platform comparability of microarray technology: intra-platform consistency and appropriate data analysis procedures are essential.
  150. (2002). Cyclindependent kinase-1: linking apoptosis to cell cycle and mitotic catastrophe.
  151. (1999). Cyclins D1 and D2 mediate myc-induced proliferation via sequestration of p27(Kip1) and p21(Cip1).
  152. (1990). Cystatin A and B in the development of human squamous epithelia.
  153. (1998). Cystatin F is a glycosylated human low molecular weight cysteine proteinase inhibitor.
  154. (1997). Cytochrome c and dATP-dependent formation of Apaf1/caspase-9 complex initiates an apoptotic protease cascade.
  155. (1995). Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor.
  156. Data Analysis Fundamentals. Affymetrix, Affymetrix (2002b). GeneChip® Expression Analysis: Data Analysis Fundamentals. Affymetrix,
  157. (2003). DAVID: Database for Annotation, Visualization, and Integrated Discovery.
  158. (2001). Deconstructing myc.
  159. (1997). Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2.
  160. (2004). Defining the temporal requirements for Myc in the progression and maintenance of skin neoplasia.
  161. (1994). Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis.
  162. (2002). Design and implementation of microarray gene expression markup language (MAGE-ML).
  163. (2003). Design considerations for efficient and effective microarray studies.
  164. (2002). Design issues for cDNA microarray experiments.
  165. (1999). Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize Myc.
  166. (2002). Diagnosis of multiple cancer types by shrunken centroids of gene expression.
  167. (1993). Differential modulation of cyclin gene expression by MYC.
  168. (1993). Differential patterns of DNA binding by myc and max proteins.
  169. (2004). Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis.
  170. (1999). Direct activation of TERT transcription by c-MYC.
  171. (1999). Direct induction of cyclin 380 D2 by Myc contributes to cell cycle progression and sequestration of p27.
  172. (2004). Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity.
  173. (2007). Discovery of novel epigenetic markers in non-Hodgkin's lymphoma.
  174. (1999). Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Mycinduced lymphomagenesis.
  175. (2005). DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis.
  176. (2000). DNA damage-induced activation of p53 by the checkpoint kinase Chk2.
  177. (2007). DNA microarrays: a powerful genomic tool for biomedical and clinical research.
  178. (2007). DNA profiling by arrayCGH in acute myeloid leukemia and myelodysplastic syndromes.
  179. (1999). Drosophila myc regulates cellular growth during development.
  180. (1989). Dynamic expression pattern of the myc protooncogene in midgestation mouse embryos.
  181. (1995). Dynamics of beta-cell mass in the growing rat pancreas. Estimation with a simple mathematical model.
  182. (2002). E2F1 and c-Myc potentiate apoptosis through inhibition of NF-kappaB activity that facilitates MnSODmediated ROS elimination.
  183. (2002). Empirical bayes methods and false discovery rates for microarrays.
  184. (2007). Empirical comparison of tests for differential expression on time-series microarray experiments.
  185. (1998). Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis.
  186. (1988). Enforced expression of the c-myc oncogene inhibits cell differentiation by precluding entry into a distinct predifferentiation state in G0/G1.
  187. (2007). Enrichment or depletion of a GO category within a class of genes: which test?
  188. (1996). Ensuring recovery of intact RNA from rat pancreas.
  189. (1998). Epidermal stem cells: markers, patterning and the control of stem cell fate.
  190. (2007). Estrogen-dependent expression of the tissue kallikrein gene (Klk1) in the mouse uterus and its implications for endometrial tissue growth.
  191. (2006). Estrogens protect pancreatic beta-cells from apoptosis and prevent insulin-deficient diabetes mellitus in mice.
  192. (1997). Eukaryotic protein processing: endoproteolysis of precursor proteins.
  193. (2003). Evaluation of gene 417 expression measurements from commercial microarray platforms.
  194. (2007). Evidence for a tumour suppressive function of IGF1-binding proteins in human breast cancer. Anticancer Res,
  195. (2003). Evidence that Myc activation depletes the epidermal stem cell compartment by modulating adhesive interactions with the local microenvironment.
  196. (2005). Experimental comparison and cross-validation of the Affymetrix and Illumina gene expression analysis platforms.
  197. (2003). Exploration, normalization, and summaries of high density oligonucleotide array probe level data.
  198. (1999). Exploring expression data: identification and analysis of coexpressed genes.
  199. (2000). Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion.
  200. (2003). Expression and localization of tissue kallikrein mRNAs in human epidermis and appendages.
  201. (1996). Expression monitoring by hybridization to high-density oligonucleotide arrays.
  202. (1990). Expression of the myc proto-oncogenes in developing human fetal brain.
  203. (2000). Expression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons.
  204. (2006). Feature-level exploration of a published Affymetrix GeneChip control dataset.
  205. (1997). FLICE is activated by association with the CD95 death-inducing signaling complex (DISC).
  206. (2005). Functional epigenomics identifies genes frequently silenced in prostate cancer.
  207. (1991). Fundamentals of molecular evolution. Sinauer Associates,
  208. (2000). gamma-catenin is regulated by the APC tumor suppressor and its oncogenic activity is distinct from that of beta-catenin.
  209. (2005). Gender differences in mouse skin morphology and specific effects of sex steroids and dehydroepiandrosterone.
  210. (2002). Gene expression correlates of clinical prostate cancer behavior.
  211. (2002). Gene Expression Omnibus: NCBI gene expression and hybridization array data repository.
  212. (2005). Gene expression profiling in single cells from the pancreatic islets of Langerhans reveals lognormal distribution of mRNA levels.
  213. (2002). Gene expression profiling predicts clinical outcome of breast cancer.
  214. (2000). Gene ontology: tool for the unification of biology. The Gene Ontology Consortium.
  215. (2004). GeneChip ® Expression Analysis Technical Manual. Affymetrix,
  216. (2007). GeneSpring: GeneSpring R Integration Functions R package version 2.12.0.
  217. (2003). Genetic blockade of the insulin-like growth factor-I receptor: a promising strategy for human pancreatic cancer.
  218. (2004). Genome Sequencing Consortium
  219. (2000). Genome-wide location and function of DNA binding proteins.
  220. (2006). Genome-wide profiling of CpG methylation identifies novel targets of aberrant hypermethylation in myeloid leukemia.
  221. (1999). Genomewide analysis of DNA copy-number changes using cDNA microarrays.
  222. (2001). Genomic binding sites of the yeast cell-cycle transcription factors SBF and MBF.
  223. (2007). Genomic characterization of multiple clinical phenotypes of cancer using multivariate linear regression models.
  224. (2003). Genomic targets of the human c-Myc protein.
  225. (2003). Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations.
  226. (2004). Getting the noise out of gene arrays.
  227. (2004). Global expression analysis of gene regulatory pathways during endocrine pancreatic development.
  228. (2004). GOstat: find statistically overrepresented Gene Ontologies within a group of genes.
  229. (1991). Growth inhibition of human keratinocytes by antisense c-myc oligomer is not coupled to induction of differentiation.
  230. (1994). Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function.
  231. (1999). High density synthetic oligonucleotide arrays.
  232. (2007). High-resolution single nucleotide polymorphism array analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifications.
  233. (2003). Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies.
  234. (2007). Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix singlenucleotide-polymorphism genotyping microarrays.
  235. (2006). How accurately can we control the FDR in analyzing microarray data?
  236. (1982). Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells.
  237. Human genome U95 data set. Affymetrix,
  238. (1996). Human ICE/CED-3 protease nomenclature.
  239. (2000). Identification of a human centrosomal calmodulin-binding protein that shares homology with pericentrin.
  240. (1995). Identification of a Myc-dependent step during the formation of active G1 cyclin-cdk complexes.
  241. (2000). Identification of c-myc responsive genes using rat cDNA microarray.
  242. (2000). Identification of CDK4 as a target of c-MYC.
  243. (2000). Identification of genes differentially over-expressed in lung squamous cell carcinoma using combination of cDNA subtraction and microarray analysis. Oncogene,
  244. (1997). Identification of putative c-Myc-responsive genes: characterization of rcl, a novel growth-related gene.
  245. (2007). Identification of structural aberrations in cancer by SNP array analysis.
  246. (2006). Identification of transcriptional targets during pancreatic growth after partial pancreatectomy and exendin-4 treatment.
  247. (2003). Identifying differentially expressed genes using false discovery rate controlling procedures.
  248. (2002). Identifying genes regulated in a Myc-dependent manner.
  249. (1975). Immunohistochemical localization of human pancreatic polypeptide (HPP) to a population of islet cells.
  250. (2003). Immunohistochemical study of caspase-3-expressing cells within the pancreas of non-obese diabetic mice during cyclophosphamide-accelerated diabetes.
  251. (2003). Immunolocalization of caspase-3 in pancreatic islets of NOD mice during cyclophosphamide-accelerated diabetes.
  252. (2006). Impact of microarray data quality on genomic data submissions to the FDA.
  253. (2007). Impact of RNA degradation on gene expression profiles: assessment of different methods to reliably determine RNA quality.
  254. (2000). Importance of replication in microarray gene expression studies: statistical methods and evidence from repetitive cDNA hybridizations.
  255. (1997). In situ hybridization: methods and applications.
  256. (1999). In vivo gene expression profile analysis of human breast cancer progression.
  257. (1996). In vivo ubiquitination and proteasome-mediated degradation of p53(1).
  258. (1993). Increased expression of eukaryotic translation initiation factors eIF4E and eIF-2 alpha in response to growth induction by c-myc.
  259. (2004). Increased measurement accuracy for sequence-verified microarray probes.
  260. (2005). Independence and reproducibility across microarray platforms.
  261. (1992). Induction of apoptosis in fibroblasts by c-myc protein.
  262. (2002). Induction of c-Myc expression suppresses insulin gene transcription by inhibiting NeuroD/BETA2-mediated transcriptional activation.
  263. (2000). Induction of cyclin E-cdk2 kinase activity, E2F-dependent transcription and cell growth by Myc are genetically separable events. Embo J,
  264. (1999). Influence of increased c-Myc expression on the growth characteristics of human melanoma.
  265. (2007). Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC.
  266. (1973). Inhibition of insulin secretion by somatostatin.
  267. (1974). Inhibition of pancreatic glucagon release by somatostatin: in vitro.
  268. (2001). Insulin-like growth factor binding proteins (IGFBPs) as potential physiological substrates for human kallikreins hK2 and hK3.
  269. (1990). Insulin-like growth factor I and transforming growth factor 406 alpha as autocrine growth factors in human pancreatic cancer cell growth.
  270. Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles.
  271. (1998). Insulin-like growth factors in human breast cancer.
  272. (2001). Integrating Myc and TGF-beta signalling in cell-cycle control.
  273. (1997). Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt.
  274. (1991). Interleukin-6- and leukemia inhibitory factor-induced terminal differentiation of myeloid leukemia cells is blocked at an intermediate stage by constitutive c-myc.
  275. (1999). Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation.
  276. (2004). Intrinsic tumour suppression.
  277. (2001). Inverse regulation of cyclin B1 by c-Myc and p53 and induction of tetraploidy by cyclin B1 overexpression.
  278. (2000). Involvement of follicular stem cells in forming not only the follicle but also the epidermis.
  279. (2002). Involvement of the cohesin protein,
  280. (1982). Isolation and characterization of c-myc, a cellular homolog of the oncogene (v-myc) of avian myelocytomatosis virus strain 29.
  281. (2004). Kallikrein gene downregulation in breast cancer.
  282. (1985). L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer.
  283. (2006). Large scale copy number variation (CNV) at 14q12 is associated with the presence of genomic abnormalities in neoplasia.
  284. Large-scale genotyping of complex DNA.
  285. (2007). Large-scale identification of c-MYCassociated proteins using a combined TAP/MudPIT approach.
  286. (2000). Large-scale monitoring of host cell gene expression during HIV-1 infection using cDNA microarrays.
  287. (2005). Limma: linear models for microarray data. In: Bioinformatics and Computational Biology Solutions using R
  288. (2004). Linear models and empirical bayes methods for assessing differential expression in microarray experiments.
  289. (1978). Localization of the human SHprotease inhibitor in the epidermis. Immunofluorescent studies.
  290. (1993). Mad: a heterodimeric partner for Max that antagonizes Myc transcriptional activity.
  291. (2000). major pathway of beta-cell formation in the pancreas.
  292. (1999). Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway.
  293. (2001). Maximum likelihood estimation of optimal scaling factors for expression array normalization. In:
  294. (1996). mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein.
  295. (1997). Mdm2 promotes the rapid degradation of p53.
  296. (1977). Method for detection of specific RNAs in agarose gels by transfer to diazobenzyloxymethyl-paper and hybridization with DNA probes.
  297. (1978). Methods of Analysis of Linear Models with Unbalanced Data.
  298. (2002). Mice overexpressing placenta growth factor exhibit increased vascularization and vessel permeability.
  299. (2004). Microarray reality checks in the context of a complex disease.
  300. (1999). Microarray Suite User Guide: Version 4. Affymetrix,
  301. (2007). Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy.
  302. (2006). Microarray-based DNA methylation profiling: technology and applications.
  303. (2006). Microarray-based molecular margin methylation pattern analysis in colorectal carcinoma.
  304. (2006). Microarray-based survey of CpG islands identifies concurrent hyper- and hypomethylation patterns in tissues derived from patients with breast cancer.
  305. (2005). MiMiR: a comprehensive solution for storage, annotation and exchange of microarray data.
  306. (2001). Minimum information about a microarray experiment (MIAME)-toward standards for microarray data.
  307. (2001). Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection.
  308. (2003). Moderate degradation does not preclude microarray analysis of small amounts of RNA.
  309. (1996). Modulation of c-Myc activity and apoptosis in vivo.
  310. (2001). Molecular biology. Glimpses of a tiny RNA world.
  311. (2000). Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex.
  312. (1999). Molecular classification of cancer: class discovery and class prediction by gene expression monitoring.
  313. (2004). Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression.
  314. (2000). Molecular portraits of human breast tumours.
  315. (2001). Morphogenesis and renewal of hair follicles from adult multipotent stem cells.
  316. (2001). Mouse testicular Leydig cells express Klk21, a tissue kallikrein that cleaves fibronectin and IGF-binding protein-3.
  317. (2007). mouse4302: Affymetrix Mouse Genome 430 2.0 Array Annotation Data. R package version 2.0.1.
  318. (1997). Movement of Bax from the cytosol to mitochondria during apoptosis.
  319. (1997). mRNA stability and the control of gene expression.
  320. (2001). Multiclass cancer diagnosis using tumor gene expression signatures.
  321. (2004). Multiple celltype-specific elements regulate Myc protein stability.
  322. (2003). Multiple Hypothesis Testing in Microarray Experiments.
  323. (2005). Multiple-laboratory comparison of microarray platforms.
  324. (2007). multtest: Resamplingbased multiple hypothesis testing. R package version 1.18.0.
  325. (1987). myc and E1A oncogenes alter the responses of PC12 cells to nerve growth factor and block differentiation.
  326. (1992). Myc and Max proteins possess distinct transcriptional activities.
  327. (1998). Myc and the cell cycle.
  328. (1995). Myc but not Fos rescue of PDGF signalling block caused by kinase-inactive Src.
  329. (2004). MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer.
  330. (1999). MYC oncogenes and human neoplastic disease.
  331. (1996). Myc oncogenes: the enigmatic family.
  332. (2003). Myc pathways provoking cell suicide and cancer.
  333. (2001). Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3.
  334. (1998). Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization.
  335. (1997). Myc target genes.
  336. (2000). Myc-enhanced expression of Cul1 promotes ubiquitin-dependent proteolysis and cell cycle progression.
  337. (1994). Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1.
  338. (1998). MycN and IFNgamma cooperate in apoptosis of human neuroblastoma cells.
  339. (1993). Myeloblastic leukemia cells conditionally blocked by myc-estrogen receptor chimeric transgenes for terminal differentiation coupled to growth arrest and apoptosis.
  340. (2004). Navigating chemical space for biology and medicine.
  341. (2002). Negative regulation of the mammalian UV response by Myc through association with Miz-1. Mol Cell,
  342. (1980). Neoplastic growths in chickens treated with cell and cell-free material from transplantable hepatoma induced by virus strain MC-29.
  343. (2005). New approaches for modelling cancer mechanisms in the mouse.
  344. (1981). Nonparametric Estimates of Standard Error: The Jackknife, the Bootstrap and Other Methods.
  345. (2007). Nontranscriptional control of DNA replication by c-Myc.
  346. (2003). Normality of oligonucleotide microarray data and implications for parametric statistical analyses. Bioinformatics,
  347. (1990). Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2.
  348. (1994). Nuclear c-Myc plays an important role in the cytotoxicity of tumor necrosis factor alpha in tumor cells.
  349. (1984). Nuclear localization and DNA binding properties of a protein expressed by human c-myc oncogene.
  350. (1999). Nuclear localization of Cdc25 is regulated by DNA damage and a 14-3-3 protein.
  351. (2005). Oligomeric Bax is a component of the putative cytochrome c release channel MAC, mitochondrial apoptosis-induced channel.
  352. (1986). On the History of ANOVA in Unbalanced Designs: The First 30 Years.
  353. (1994). Oncogenes and cell death.
  354. (1993). Oncogenic activity of the c-Myc protein requires dimerization with Max.
  355. (1998). Ontologies for molecular biology. Pac Symp Biocomput:
  356. (2002). Optimal gene expression analysis by microarrays.
  357. (2000). Out of Eden: stem cells and their niches.
  358. (2000). Overexpression of Bcl-x(L) in beta-cells prevents cell death but impairs mitochondrial signal for insulin secretion.
  359. (2002). Overexpression of c-Myc in beta-cells of transgenic mice causes proliferation and apoptosis, downregulation of insulin gene expression, and diabetes.
  360. (2001). OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells.
  361. (2004). p19ARF directly and differentially controls the functions of c-Myc independently of p53.
  362. (2003). p19ARF-induced p53-independent apoptosis largely occurs through BAX.
  363. (2000). p21-activated kinase 1 phosphorylates the death agonist bad and protects cells from apoptosis.
  364. (2003). p53 has a direct apoptogenic role at the mitochondria.
  365. (2000). p53-independent functions of the p19(ARF) tumor suppressor.
  366. (2002). Pancreas duodenum homeobox-1 regulates pancreas development during embryogenesis and islet cell function in adulthood.
  367. (2005). Pancreatic beta-cell failure and diabetes in mice with a deletion mutation of the endoplasmic reticulum molecular chaperone gene P58IPK.
  368. (1996). Parallel human genome analysis: microarray-based expression monitoring of 1000 genes.
  369. (2006). Performance comparison of one-color and two-color 407 platforms within the MicroArray Quality Control (MAQC) project.
  370. (1996). Plectin sidearms mediate interaction of intermediate filaments with microtubules and other components of the cytoskeleton.
  371. (2001). Plk3 functionally links DNA damage to cell cycle arrest and apoptosis at least in part via the p53 pathway.
  372. (2002). Post-analysis follow-up and validation of microarray experiments.
  373. (2000). Posttranscriptional deregulation of myc genes in lung cancer cell lines.
  374. (2005). Preferred analysis methods for Affymetrix GeneChips revealed by a wholly defined control dataset.
  375. (2000). Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c.
  376. (1996). Proapoptotic protein Bax heterodimerizes with Bcl-2 and homodimerizes with Bax via a novel domain (BH3) distinct from BH1 and BH2.
  377. (2006). Prognostic DNA methylation biomarkers in ovarian cancer.
  378. (1990). Prognostic significance of insulin-like growth factor 1 receptors in human breast cancer.
  379. (1997). Proliferation and differentiation in the human fetal endocrine pancreas.
  380. (2001). Promoter-specific binding of Rap1 revealed by genome-wide maps of protein-DNA association.
  381. (1996). Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue.
  382. (1987). Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.
  383. (1996). Proteins of the Myc network: essential regulators of cell growth and differentiation.
  384. (2000). Proteomics to study genes and genomes.
  385. (2001). Purification and characterization of human DNA damage checkpoint Rad complexes.
  386. (2007). QA/QC issues to aid regulatory acceptance of microarray gene expression data.
  387. (2001). Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker.
  388. (1995). Quantitative monitoring of gene expression patterns with a complementary DNA microarray.
  389. (1996). R: A Language for Data Analysis and Graphics.
  390. (1997). Ratio-based decisions and quantitative analysis of cDNA microarray images.
  391. (1996). Real time quantitative PCR.
  392. (2005). Real-Time PCR Systems: Applied Biosystems 7900HT fast real-time PCR system and 7300/7500 real-time PCR systems chemistry guide. Applied Biosystems,
  393. (2001). Reconstitution and molecular analysis of the hRad9-hHus1-hRad1 (9-1-1) DNA damage responsive checkpoint complex.
  394. (1996). Regression Shrinkage and Selection via the LASSO.
  395. (2007). Regulated -cell regeneration in the adult mouse pancreas.
  396. (2002). Regulation of ATR substrate selection by
  397. (2001). Regulation of c-myc expression by PDGF through Rho GTPases.
  398. (2001). Regulation of cyclin D2 gene expression by the Myc/Max/Mad network: Myc-dependent TRRAP recruitment and histone acetylation at the cyclin D2 promoter.
  399. (2003). Regulation of hypoxiainducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer.
  400. (2001). Regulation of mRNA stability in mammalian cells.
  401. Regulation of the mitochondrial apoptosis-induced channel, MAC, by BCL-2 family proteins.
  402. (1995). Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene.
  403. (1997). Repression of c-Myc responsive genes in cycling cells causes G1 arrest through reduction of cyclin E/CDK2 kinase activity.
  404. (1994). Repression of cyclin D1: a novel function of MYC.
  405. (2001). Repression of p15INK4b expression by Myc through association with Miz-1.
  406. (2001). Repression of transcription of the p27(Kip1) cyclindependent kinase inhibitor gene by c-Myc. Oncogene,
  407. (2007). Reproducible and reliable microarray results through quality control: good laboratory proficiency and appropriate data analysis practices are essential. Curr Opin Biotechnol.
  408. Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis.
  409. (1999). Requirement of ATMdependent phosphorylation of brca1 in the DNA damage response to doublestrand breaks.
  410. (2003). Requirement of different signaling pathways mediated by insulin-like growth factor-I receptor for proliferation, invasion, and VPF/VEGF expression in a pancreatic carcinoma cell line.
  411. (1999). Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion.
  412. (2006). Reversible kinetic analysis of Myc targets in vivo provides novel insights into Myc-mediated tumorigenesis.
  413. (2004). Reversible lymphomagenesis in conditionally c-MYC expressing mice.
  414. (2005). RNA polymerases I and III, growth control and cancer.
  415. (2002). Robust estimators for expression analysis.
  416. (1992). Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas.
  417. (1998). Role of plectin in cytoskeleton organization and dynamics.
  418. (1950). Second carbohydrate metabolism hormone of the pancreas (glucagon) and its origin in the alpha cells.]. Klin Wochenschr,
  419. (2001). Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation.
  420. (1995). Self organising maps.
  421. (1990). Sequence-specific DNA binding by the c-Myc protein.
  422. (1995). Serial analysis of gene expression.
  423. (2002). Severe block in processing of proinsulin to insulin accompanied by elevation of des-64,65 proinsulin intermediates in islets of mice lacking prohormone convertase 1/3. Proc Natl Acad Sci
  424. (2001). Severe defect in proglucagon processing in islet A-cells of prohormone convertase 2 null mice.
  425. (2007). Sic Transit Gloria: Farewell to the epidermal transit amplifying cell?
  426. (2007). Single nucleotide polymorphism array analysis of chromosomal instability patterns discriminates rectal adenomas from carcinomas.
  427. (2006). Single-cell expression profiling of human epidermal stem and transit-amplifying cells: Lrig1 is a regulator of stem cell quiescence.
  428. (2005). Single-chain tissue-type plasminogen activator is a substrate of mouse glandular kallikrein 24.
  429. (2003). Skp2 regulates Myc protein stability and activity.
  430. (2000). Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition.
  431. (2003). Solving the riddle of the bright mismatches: labeling and effective binding in oligonucleotide arrays.
  432. (1974). Somatostatin: hypothalamic inhibitor of the endocrine pancreas.
  433. (1991). Specific activation of cdc25 tyrosine phosphatases by B-type cyclins: evidence for multiple roles of mitotic cyclins.
  434. (2006). Specific requirement for Bax, not Bak, in Myc-induced apoptosis and tumor suppression in vivo.
  435. (2005). Standardizing global gene expression analysis between laboratories and across platforms.
  436. (2001). Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis.
  437. (2001). Statistical analysis of high density oligonucleotide arrays: a SAFER approach.
  438. (2001). Statistical design and the analysis of gene expression microarray data.
  439. (2002). Statistical issues with microarrays: processing and analysis.
  440. (2003). Statistical tests for differential expression in cDNA microarray experiments.
  441. (2003). Statistical tests for identifying differentially expressed genes in timecourse microarray experiments.
  442. (1979). Stem cell concepts.
  443. (2003). Stem cells of the skin epithelium.
  444. (2003). Stimulation of c-MYC transcriptional activity and acetylation by recruitment of the cofactor CBP.
  445. (2005). Stress-induced p53 runs a transcriptionindependent death program.
  446. (2006). Structural variants: changing the landscape of chromosomes and design of disease studies.
  447. (1986). Structure and evolution of the human involucrin gene.
  448. (2003). Summaries of Affymetrix GeneChip probe level data.
  449. Suppression of aging in mice by the hormone Klotho.
  450. (1997). Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB.
  451. (2002). Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression.
  452. (2000). Surfing the p53 network.
  453. (2002). Sustained loss of a neoplastic phenotype by brief inactivation of MYC.
  454. (1995). Synergy between a human c-myc transgene and p53 null genotype in murine thymic lymphomas: contrasting effects of homozygous and heterozygous p53 loss.
  455. (2005). Targeting c-Myc-activated genes with a correlation method: detection of global changes in large gene expression network dynamics.
  456. (2006). Targeting of Miz-1 is essential for Mycmediated apoptosis.
  457. (2000). tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c.
  458. (1936). Teoria statistica delle classi e calcolo delle probabilità.
  459. (2001). TGF-beta flips the Myc switch.
  460. (1998). The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2.
  461. (2003). The Analysis of Gene Expression Data: An Overview of Methods and Software.
  462. (1934). The analysis of multiple classifications with unequal numbers in the different classes.
  463. (1926). The Arrangement of Field Experiments.
  464. (1989). The BCR-ABL oncogene transforms Rat-1 cells and cooperates with v-myc.
  465. (1985). The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice.
  466. (1993). The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1 beta-converting enzyme.
  467. (1993). The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14.
  468. (1997). The central executioner of apoptosis: multiple connections between protease activation and mitochondria in Fas/APO-1/CD95- and ceramide-induced apoptosis.
  469. (2001). The contributions of sex, genotype and age to transcriptional variance in Drosophila melanogaster.
  470. (2001). The control of the false discovery rate in multiple testing under dependency.
  471. (2004). The emerging roles of human tissue kallikreins in cancer.
  472. (2000). The exosome: a conserved eukaryotic RNA processing complex containing multiple 3'-->5' exoribonucleases.
  473. (2003). The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription.
  474. (1990). The FT210 cell line is a mouse G2 phase mutant with a temperature-sensitive CDC2 gene product.
  475. (2005). The haploinsufficient tumor suppressor p18 upregulates p53 via interactions with ATM/ATR.
  476. (2000). The human homologs of checkpoint kinases
  477. (2003). The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects.
  478. (1994). The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects.
  479. (1997). The lasso method for variable selection in the Cox model.
  480. (2003). The many faces of c-MYC.
  481. (1992). The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.
  482. (2006). The microarray data analysis process: from raw data to biological significance.
  483. (2006). The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements.
  484. (1995). The MMTV/c-myc transgene and p53 null alleles collaborate to induce T-cell lymphomas, but not mammary carcinomas in transgenic mice.
  485. (1999). The Myc oncoprotein: a critical evaluation of transactivation and target gene regulation.
  486. (2007). The Myc transactivation domain promotes global phosphorylation of the RNA polymerase II carboxy-terminal domain independently of direct DNA binding.
  487. (2000). The Myc/Max/Mad network and the transcriptional control of cell behavior.
  488. (1998). The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins.
  489. (1999). The pro-apoptotic proteins, Bid and Bax, cause a limited permeabilization of the mitochondrial outer membrane that is enhanced by cytosol.
  490. (1998). The proprotein convertases.
  491. (2001). The R-Tcl/Tk Interface.
  492. (2006). The RIN: an RNA integrity number for assigning integrity values to RNA measurements.
  493. (2000). The role of bim, a proapoptotic BH3-only member of the Bcl-2 family in cell-death control.
  494. (1963). The stimulation of epidermal keratinization by a protein isolated from the submaxillary gland of the mouse.
  495. (2001). The transcriptional program of a human B cell line in response to Myc.
  496. (2007). The utility of MAS5 expression summary and detection call algorithms.
  497. (2005). Three microarray platforms: an analysis of their concordance in profiling gene expression.
  498. (1979). Three new types of viral oncogene of cellular origin specific for haematopoietic cell transformation.
  499. (2002). Three-dimensional structure of the apoptosome: implications for assembly, procaspase-9 binding, and activation.
  500. (2000). Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation.
  501. (1992). Tissue-specific expression of kallikrein family transgenes in mice and rats.
  502. (2002). TNF-R1 signaling: a beautiful pathway.
  503. (2003). Transcription factors direct the development and function of pancreatic beta cells.
  504. (1992). Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max.
  505. (2002). Transcriptional regulatory networks in Saccharomyces cerevisiae.
  506. (2003). Transformations for cDNA microarray data.
  507. (1999). Transient excess of MYC activity can elicit genomic instability and tumorigenesis.
  508. (2004). Tumor Analysis Best Practices Working Group
  509. (2003). Tumor necrosis factor signaling.
  510. (1983). Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes.
  511. (2003). TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor.
  512. (2000). Understanding robust and exploratory data analysis.
  513. (2006). Unravelling the dynamics of RNA degradation by ribonuclease II and its RNA-bound complex.
  514. (1996). Use of a cDNA microarray to analyse gene expression patterns in human cancer.
  515. (1994). Use of transgenic mice to study myc family gene function in normal mammalian development and in cancer.
  516. (2003). Using ANOVA for gene selection from microarray studies of the nervous system.
  517. (2004). Using ANOVA to analyze microarray data.
  518. (2001). Validation of array-based gene expression profiles by real-time (kinetic)
  519. (2002). Variance stabilization applied to microarray data calibration and to the quantification of differential expression.
  520. (1993). Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B.
  521. (1999). Withdrawal of IL-7 induces Bax translocation from cytosol to mitochondria through a rise in intracellular pH.
  522. (1948). Zwischenmolekulare energiewanderung und fluoreszenz.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.